ClinicalTrials.gg
CompletedNCT01079806Updated May 9, 2019Results posted

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

A Phase 3 interventional study of Entecavir and Placebo in Chronic Hepatitis B Virus, Pediatric, sponsored by Bristol-Myers Squibb. Completed at 44 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-05-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
19th of 61
180 · median 109
Started
2010
with 5 others
Phase 3
13 of 64
none open now
Registered
30th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 19th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2010, is one of 13 in phase 3, and was the 30th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection

03

Conditions studied

  • Chronic Hepatitis B Virus, Pediatric

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Males and females, aged 2 to \<18 years
  • surface antigen-positive
  • Detectable hepatitis B e (HBe) antigen, and no detectable anti-HBe antibodies
  • (ALT) 1.5 to \<10 times the at screening and within 8 to 24 weeks prior to screening
  • Evidence of the presence of hepatitis B virus DNA at least 4 weeks before screening and >100,000 copies/mL at screening

Key Exclusion Criteria

  • Any prior therapy with entecavir
  • At least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent
  • Therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within 24 weeks of screening
  • Coinfection with , virus, or hepatitis D virus
  • Decompensated liver disease
  • Liver transplant recipients
  • Other forms of acute and chronic conditions which may cause increased ALT levels
  • Children who were breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Active comparator
    Entecavir

    Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response

    Drug: Entecavir

  • Placebo comparator
    Placebo

    Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response

    Drug: Placebo

Interventions

  • Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response

    Also known as: Baraclude, BMS-200475

  • DrugPlacebo

    Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48

    Suppression=HBV DNA\<50 IU/mL (approximately 300 copies/mL) using the Roche COBAS TaqMan HBV Test for use with the High Pure System assay; seroconversion=undetectable HBeAg and detectable anti-hepatitis B e antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48

    While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

    Time frame: At Week 48

  2. Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48

    While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

    Time frame: At Week 48

  3. Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48

    LOQ=29 IU/mL. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

    Time frame: At Week 48

  4. Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)

    Percentage of participants in the primary cohort with HBeAg seroconversion (undetectable HBeAg and presence of anti-HBe antibodies) at week 48

    Time frame: At Week 48

  5. Percentage of Participants Who Achieved Sustained HBeAg Seroconversion During Off-treatment Follow up Among Participants Who Achieved HBeAg Seroconversion at End of Dosing (EOD).

    Participants who demonstrated HBeAg seroconversion at EOD were followed and assessed for presence of sustained HBeAg seroconversion during entire study. The study reached the end of dosing (EOD) on 22 Feb-2016.

    Time frame: Week 48, EOD (2 years)

  6. Number of Participants With Adverse Events (Including Palatability Issues), SAEs, Discontinuous Due to Adverse Events, and HBV Disease Progression Through Week 48

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.

    Time frame: Day 1 through Week 48 on blinded therapy

  7. Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)

    Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. INR=international normalization ratio of prothrombin time; ULN=upper limit of normal. Hemoglobin (g/dL): Grade 1=10-10.9; Grade 2=9-9.9; Grade 3=7-8.9; Grade 4= \<7. Platelets (/mm\^3): Grade 1=100,000-124,999; Grade 2=50,000-99,999; Grade 3=25,000-49,999; Grade 4= \<25,000. INR (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-2; Grade 3=2.1-3; Grade 4= \>3. WBC (/mm\^3): Grade 1=2000-2500; Grade 2=1500-1999; Grade 3=1000-1499; Grade 4= \<1000. Neutrophils (/mm\^3): Grade 1=1000-1300; Grade 2=750-999; Grade 3=500-749; Grade 4= \<500.

    Time frame: Day 1 through Week 48 on blinded therapy

  8. Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)

    Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; ULN=upper limit of normal; LLN=lower limit of normal. ALT, AST (\*ULN): Grade 1=1.25-2; Grade 2=2.6-5; Grade 3=5.1-10; Grade 4 =\> 10. Bilirubin (\*ULN): Grade 1 = 1.1-1.5; Grade 2=1.6-2.5; Grade 3 = 2.6-5; Grade 4= \>5. Albumin (g/dL): Grade 1=3- \<LLN; Grade 2=2-2.9; Grade 3= \<2. Lipase (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-3; Grade 3=3.1-5; Grade 4= \>5. BUN/urea (\*ULN): Grade 1=1.25-\<2.6; Grade 2=2.6-\<5.1; Grade 3=5.1-10; Grade 4= \>10. Chloride, high (mEq/L): Grade 1=113-\<117; Grade 2=117-\<121; Grade 3=121-125; Grade 4= \>125. Potassium, low (mEq/L): Grade 1=3-3.4; Grade 2=2.5-\<3; Grade 3=2-\<2.5; Grade 4=\<2. Potassium, high (mEq/L): : Grade 1= 5.6-\<6.1; Grade 2=6.1-\<6.6; Grade 3=6.6-7; Grade 4= \>7. Sodium, high (mEq/L): Grade 1=146\<151; Grade 2=151-\<155; Grade 3=155-\<160; Grade 4= \>=160.

    Time frame: Day 1 through Week 48 on blinded therapy

  9. Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)

    HBe seroconversion=undetectable HBe antigen and detectable anti-HBe antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

    Time frame: At Week 96

  10. Percentage of Participants Who Maintained HBeAg Seroconversion at Week 96 (End of Blinded Therapy) Among Participants With HBeAg Seroconversion at Week 48

    Participants who achieved HBeAg seroconversion by Week 48 and maintained seroconversion to week 96

    Time frame: At Week 96

  11. Percentage of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression Through Week 96

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.

    Time frame: Day 1 through Week 96

  12. Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96

    On Treatment through week 96 - 2 year cohort NC = F: (The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures.)

    Time frame: up to week 96

  13. Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data

    Liver function test elevations and abnormalities on blinded and open-label ETV (the All ETV Safety Cohort). Participants who experienced elevation of alanine aminotransferase (ALT) greater than three times ETV (entecavir) baseline measure (Participants who displayed liver biopsy with ALT value greater than three times baseline.)

    Time frame: Between weeks 48 and 96

  14. Percentage of Participants With HbeAg Loss at Weeks 48 and 96

    HBeAg Loss (NC = F and NC = M) - On Treatment through Week 96 - Year 2 Efficacy Cohort Non-Completer - Failure (NC=F): The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures. Non-Completer - Missing (NC=M): The numerator was based on participants meeting the response criteria. The denominator was based on participants with data at the analysis week. Participants who had missing data at the analysis week were excluded.

    Time frame: At 48 and 96 weeks

07

Results

Posted Apr 21, 2014

Participant flow

Day 1 to Week 96
Participant flow — Day 1 to Week 96
MilestoneEntecavirPlacebo
Started12060
Received treatment12060
Primary endpoint cohort8241
Completed11353
Not completed77
Withdrew: Adverse event03
Withdrew: Withdrawal by subject32
Withdrew: Pregnancy01
Withdrew: Poor compliance or noncompliance20
Withdrew: Lost to follow-up10
Withdrew: Subject request to stop study treatment10
Withdrew: Removal by medical monitor01
Long-term Follow-up: Day 1-End of Study
Participant flow — Long-term Follow-up: Day 1-End of Study
MilestoneEntecavirPlacebo
Started11158
Completed9243
Not completed1915
Withdrew: Withdrawal by subject138
Withdrew: Investigator left institution01
Withdrew: Lost to follow-up66

Outcome measures

PrimaryPercentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48

Suppression=HBV DNA\<50 IU/mL (approximately 300 copies/mL) using the Roche COBAS TaqMan HBV Test for use with the High Pure System assay; seroconversion=undetectable HBeAg and detectable anti-hepatitis B e antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
Percentage of participantsEntecavirPlacebo
Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 4824.42.4
Statistical analysis
  • Entecavir vs Placebo · Normal approximation · p = 0.0049 · Difference estimate: 20.2 · 95% CI 9.1 to 31.4Difference estimate is stratified by age randomization strata, using Cochran-Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48

While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48
Percentage of participantsEntecavirPlacebo
Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 4846.32.4
Statistical analysis
  • Entecavir vs Placebo · Normal approximation · p = <0.0001 · Difference estimate: 41.8 · 95% CI 29.4 to 54.2Difference estimate is stratified by age randomization strata, using Cochran-Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48

While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48
Percentage of participantsEntecavirPlacebo
Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 4867.122.0
Statistical analysis
  • Entecavir vs Placebo · Normal approximation · p = <0.0001 · Difference estimate: 45.2 · 95% CI 29.2 to 61.2Difference estimate is stratified by age randomization strata, using Cochran-Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48

LOQ=29 IU/mL. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48
Percentage of participantsEntecavirPlacebo
Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 4842.72.4
Statistical analysis
  • Entecavir vs Placebo · Normal approximation · p = <0.0001 · Difference estimate: 38.2 · 95% CI 25.9 to 50.5Difference estimate is stratified by age randomization strata, using Cochran-Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)

Percentage of participants in the primary cohort with HBeAg seroconversion (undetectable HBeAg and presence of anti-HBe antibodies) at week 48

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)
Percentage of participantsEntecavirPlacebo
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)24.412.2
Statistical analysis
  • Entecavir vs Placebo · Normal approximation · p = 0.11 · Difference estimate: 12.1 · 95% CI -1.5 to 25.7Difference estimate is stratified by age randomization strata, using Cochran-Mantel-Haenszel weighting.
SecondaryPercentage of Participants Who Achieved Sustained HBeAg Seroconversion During Off-treatment Follow up Among Participants Who Achieved HBeAg Seroconversion at End of Dosing (EOD).

Participants who demonstrated HBeAg seroconversion at EOD were followed and assessed for presence of sustained HBeAg seroconversion during entire study. The study reached the end of dosing (EOD) on 22 Feb-2016.

Time frame:
Week 48, EOD (2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Sustained HBeAg Seroconversion During Off-treatment Follow up Among Participants Who Achieved HBeAg Seroconversion at End of Dosing (EOD).
Percentage of participantsEntecavirPlacebo
EOD (end of dosing)100.0100.0
Week 4874.459.1
SecondaryNumber of Participants With Adverse Events (Including Palatability Issues), SAEs, Discontinuous Due to Adverse Events, and HBV Disease Progression Through Week 48

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.

Time frame:
Day 1 through Week 48 on blinded therapy
Reported as:
Number · participants
Number of Participants With Adverse Events (Including Palatability Issues), SAEs, Discontinuous Due to Adverse Events, and HBV Disease Progression Through Week 48
participantsEntecavirPlacebo
Deaths00
Serious Adverse Events47
Discontinuation due to Adverse Event02
any adverse event7846
Related Adverse Events116
Related Grade 2 - 4 Adverse Events42
Grade 3 - 4 Adverse Events43
ALT Flares25
HBV disease progression00
Malignant neoplasms or pre-malignant lesions00
SecondaryNumber of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)

Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. INR=international normalization ratio of prothrombin time; ULN=upper limit of normal. Hemoglobin (g/dL): Grade 1=10-10.9; Grade 2=9-9.9; Grade 3=7-8.9; Grade 4= \<7. Platelets (/mm\^3): Grade 1=100,000-124,999; Grade 2=50,000-99,999; Grade 3=25,000-49,999; Grade 4= \<25,000. INR (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-2; Grade 3=2.1-3; Grade 4= \>3. WBC (/mm\^3): Grade 1=2000-2500; Grade 2=1500-1999; Grade 3=1000-1499; Grade 4= \<1000. Neutrophils (/mm\^3): Grade 1=1000-1300; Grade 2=750-999; Grade 3=500-749; Grade 4= \<500.

Time frame:
Day 1 through Week 48 on blinded therapy
Reported as:
Number · Participants
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)
ParticipantsEntecavirPlacebo
Hemoglobin54
Platelets32
INR26
White blood cells (WBC)21
Neutrophils + bands (absolute)142
SecondaryNumber of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)

Toxicities graded per Division of AIDS criteria, Version 1.0, and modified World Health Organization criteria. ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; ULN=upper limit of normal; LLN=lower limit of normal. ALT, AST (\*ULN): Grade 1=1.25-2; Grade 2=2.6-5; Grade 3=5.1-10; Grade 4 =\> 10. Bilirubin (\*ULN): Grade 1 = 1.1-1.5; Grade 2=1.6-2.5; Grade 3 = 2.6-5; Grade 4= \>5. Albumin (g/dL): Grade 1=3- \<LLN; Grade 2=2-2.9; Grade 3= \<2. Lipase (\*ULN): Grade 1=1.1-1.5; Grade 2=1.6-3; Grade 3=3.1-5; Grade 4= \>5. BUN/urea (\*ULN): Grade 1=1.25-\<2.6; Grade 2=2.6-\<5.1; Grade 3=5.1-10; Grade 4= \>10. Chloride, high (mEq/L): Grade 1=113-\<117; Grade 2=117-\<121; Grade 3=121-125; Grade 4= \>125. Potassium, low (mEq/L): Grade 1=3-3.4; Grade 2=2.5-\<3; Grade 3=2-\<2.5; Grade 4=\<2. Potassium, high (mEq/L): : Grade 1= 5.6-\<6.1; Grade 2=6.1-\<6.6; Grade 3=6.6-7; Grade 4= \>7. Sodium, high (mEq/L): Grade 1=146\<151; Grade 2=151-\<155; Grade 3=155-\<160; Grade 4= \>=160.

Time frame:
Day 1 through Week 48 on blinded therapy
Reported as:
Number · participants
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)
participantsEntecavirPlacebo
ALT11359
AST8751
Total bilirubin56
Albumin01
Lipase3820
BUN/Urea102
Chloride, high21
Potassium, low11
Potassium, high10
Sodium, high84
SecondaryPercentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)

HBe seroconversion=undetectable HBe antigen and detectable anti-HBe antibodies. While the analysis of the primary endpoint was based on a randomized sample size of 123 participants (the Primary Cohort), the size of the overall study population was augmented to 180 randomized participants to meet global regulatory requirements.

Time frame:
At Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)
Percentage of participantsBlinded and Open-Label (All ETV)
Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)38.6
SecondaryPercentage of Participants Who Maintained HBeAg Seroconversion at Week 96 (End of Blinded Therapy) Among Participants With HBeAg Seroconversion at Week 48

Participants who achieved HBeAg seroconversion by Week 48 and maintained seroconversion to week 96

Time frame:
At Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Maintained HBeAg Seroconversion at Week 96 (End of Blinded Therapy) Among Participants With HBeAg Seroconversion at Week 48
Percentage of participantsEntecavirPlacebo
Week 4824.210.0
Week 9636.720.0
SecondaryPercentage of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression Through Week 96

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death. ALT=alanine aminotransferase.

Time frame:
Day 1 through Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression Through Week 96
Percentage of participantsBlinded and Open-Label (All ETV)
Deaths0
SAEs4.7
Discontinuations due to AEs0.6
Related AEs8.2
Grade 2-4 Related AEs2.3
Grade 3-4 AEs4.1
Malignancies0
ALT flares1.8
Hepatic disease progression0
SecondaryPercentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96

On Treatment through week 96 - 2 year cohort NC = F: (The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures.)

Time frame:
up to week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96
Percentage of participantsEntecavir
Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 9640.8
SecondaryHistological Analysis (Percentage) Among Participants With Available Liver Biopsy Data

Liver function test elevations and abnormalities on blinded and open-label ETV (the All ETV Safety Cohort). Participants who experienced elevation of alanine aminotransferase (ALT) greater than three times ETV (entecavir) baseline measure (Participants who displayed liver biopsy with ALT value greater than three times baseline.)

Time frame:
Between weeks 48 and 96
Reported as:
Number · Percentage of participants
Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data
Percentage of participantsBlinded and Open-Label (All ETV)
Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data5.9
SecondaryPercentage of Participants With HbeAg Loss at Weeks 48 and 96

HBeAg Loss (NC = F and NC = M) - On Treatment through Week 96 - Year 2 Efficacy Cohort Non-Completer - Failure (NC=F): The numerator was based on participants meeting the response criteria. The denominator was based on treated participants. Participants who had missing data at the analysis week were considered failures. Non-Completer - Missing (NC=M): The numerator was based on participants meeting the response criteria. The denominator was based on participants with data at the analysis week. Participants who had missing data at the analysis week were excluded.

Time frame:
At 48 and 96 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With HbeAg Loss at Weeks 48 and 96
Percentage of participantsEntecavirPlacebo
48 weeks25.010.0
96 Weeks40.8—

Adverse events

Collected over All non-serious adverse events were collected from start of study treatment through Week 48, while all serious adverse events were evaluated through out the study (5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETV (Entecavir)0/120 (0%)4/120 (3.3%)76/120 (63.3%)
PLACEBO0/60 (0%)9/60 (15%)45/60 (75%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventETV (Entecavir)PLACEBO
Hepatic function abnormalHepatobiliary disorders0/1202/60
GastritisGastrointestinal disorders0/1201/60
Inflammatory bowel diseaseGastrointestinal disorders0/1201/60
CellulitisInfections and infestations0/1201/60
Chronic hepatitis bInfections and infestations0/1201/60
Infectious colitisInfections and infestations0/1201/60
MastoiditisInfections and infestations0/1201/60
PharyngitisInfections and infestations0/1201/60
Diabetic ketoacidosisMetabolism and nutrition disorders0/1201/60
ArthralgiaMusculoskeletal and connective tissue disorders0/1201/60
Most frequent other events
Showing 10 of 27
Most frequent other events
EventETV (Entecavir)PLACEBO
NasopharyngitisInfections and infestations18/12014/60
Upper respiratory tract infectionInfections and infestations19/12012/60
CoughRespiratory, thoracic and mediastinal disorders15/12012/60
PharyngitisInfections and infestations5/12011/60
VomitingGastrointestinal disorders14/12010/60
PyrexiaGeneral disorders18/12010/60
Abdominal painGastrointestinal disorders9/1209/60
HeadacheNervous system disorders18/1209/60
DiarrhoeaGastrointestinal disorders7/1207/60
BronchitisInfections and infestations8/1206/60

Baseline characteristics

All participants who received study drug

Age, Continuous
Age, Continuous(Years)EntecavirPlaceboTotal
Mean10.5 ± 4.8710.8 ± 4.8210.6 ± 4.84
Age, Customized
Age, Customized(participants)EntecavirPlaceboTotal
>=2 years to <=6 years271441
>6 years to <=12 years311546
>12 years to <18 years623193
Sex: Female, Male
Sex: Female, Male(Participants)EntecavirPlaceboTotal
Female422971
Male7831109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EntecavirPlaceboTotal
Hispanic or Latino202
Not Hispanic or Latino482169
Unknown or Not Reported7039109
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EntecavirPlaceboTotal
Asian573087
Black/African American14216
Native Hawaiian/Other Pacific Islander101
White442771
Other415
08

Study locations

44 sites
  • University Of California, San Francisco
    San Francisco, California 94143, United States
  • Connecticut Children'S Medical Center
    Hartford, Connecticut 06106, United States
  • Children'S National Medical Center
    Washington, District of Columbia 20010, United States
  • University Of Florida
    Gainesville, Florida 32610, United States
  • Romero, Rene
    Atlanta, Georgia 30322, United States
  • Indiana University School Of Medicine / Riley Hospital
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins School Of Medicine
    Baltimore, Maryland 21287, United States
  • Shah, Uzma
    Boston, Massachusetts 02114, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Levine Children'S Hospital At Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Children'S Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Texas Children'S Hospital
    Houston, Texas 77030, United States
  • Inova Fairfax Hospital For Children
    Fairfax, Virginia 22031, United States
  • Local Institution
    Bunos Aires, Buenos Aires 1425, Argentina
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution
    Mainz, Rheinland Pfalz 55131, Germany
  • Local Institution
    Starnberg, 82319, Germany
  • Local Institution
    Wuppertal, 42283, Germany
  • Local Institution
    Thesaloniki, 54635, Greece
  • Local Institution
    Guwahati, 781006, India
  • Local Institution
    Hyderabad, 500029, India
  • Local Institution
    Beer-sheva, 84101, Israel
  • Local Institution
    Petach Tikva, Israel
  • Local Institution
    Zefat, 13110, Israel
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Bydgoszcz, 85-030, Poland
  • Local Institution
    Krakow, 31-202, Poland
  • Local Institution
    Wroclaw, 50-345, Poland
  • Local Institution
    Bucharest, 011743, Romania
  • Local Institution
    Iasi, 700309, Romania
  • Local Institution
    Timisoara, 300011, Romania
  • Local Institution
    Moscow, 111123, Russian Federation
  • Local Institution
    Moscow, 117198, Russian Federation
  • Local Institution
    Novokuznetsk, 654063, Russian Federation
  • Local Institution
    St. Petersburg, 197022, Russian Federation
  • Local Institution
    Tainan, 704, Taiwan
  • Local Institution
    Taipei, 100, Taiwan
  • Local Institution
    London, Greater London SE5 9RS, United Kingdom
  • Local Institution
    Birmingham, West Midlands B4 6NH, United Kingdom
09

References and documents

Publications

  • Jonas MM, Chang MH, Sokal E, Schwarz KB, Kelly D, Kim KM, Ling SC, Rosenthal P, Oraseanu D, Reynolds L, Thiry A, Ackerman P. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology. 2016 Feb;63(2):377-87. doi: 10.1002/hep.28015. Epub 2015 Oct 16. Erratum In: Hepatology. 2017 Apr;65(4):1427. doi: 10.1002/hep.29011. PubMed 26223345 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Mar 2013, 33 months.

Results were first posted in Apr 2014, 1 year after primary completion.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 3, 2010
StartActual
Jun 30, 2010
Primary completionActual
Mar 31, 2013
CompletionActual
Mar 31, 2018
Results first posted
Apr 21, 2014
Last update
May 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01079806
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
Jun 30, 2010
Primary completion
Mar 31, 2013
Completion
Mar 31, 2018
Results posted
Apr 21, 2014
Last update
May 9, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion